SG11201504447XA - Novel pharmaceutical formulations and their use in the treatment of periodontal disease - Google Patents

Novel pharmaceutical formulations and their use in the treatment of periodontal disease

Info

Publication number
SG11201504447XA
SG11201504447XA SG11201504447XA SG11201504447XA SG11201504447XA SG 11201504447X A SG11201504447X A SG 11201504447XA SG 11201504447X A SG11201504447X A SG 11201504447XA SG 11201504447X A SG11201504447X A SG 11201504447XA SG 11201504447X A SG11201504447X A SG 11201504447XA
Authority
SG
Singapore
Prior art keywords
treatment
pharmaceutical formulations
periodontal disease
novel pharmaceutical
novel
Prior art date
Application number
SG11201504447XA
Inventor
Thomas Kissel
Ching Pong Mak
Original Assignee
Perioc Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perioc Ltd filed Critical Perioc Ltd
Publication of SG11201504447XA publication Critical patent/SG11201504447XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063Periodont
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
SG11201504447XA 2012-12-13 2013-12-13 Novel pharmaceutical formulations and their use in the treatment of periodontal disease SG11201504447XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1222455.6A GB201222455D0 (en) 2012-12-13 2012-12-13 Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
PCT/GB2013/053283 WO2014091239A1 (en) 2012-12-13 2013-12-13 Novel pharmaceutical formulations and their use in the treatment of periodontal disease

Publications (1)

Publication Number Publication Date
SG11201504447XA true SG11201504447XA (en) 2015-07-30

Family

ID=47630648

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201704712QA SG10201704712QA (en) 2012-12-13 2013-12-13 Novel pharmaceutical formulations and their use in the treatment of periodontal disease
SG11201504447XA SG11201504447XA (en) 2012-12-13 2013-12-13 Novel pharmaceutical formulations and their use in the treatment of periodontal disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201704712QA SG10201704712QA (en) 2012-12-13 2013-12-13 Novel pharmaceutical formulations and their use in the treatment of periodontal disease

Country Status (11)

Country Link
US (2) US10471058B2 (en)
EP (2) EP3498290A1 (en)
JP (2) JP6441809B2 (en)
KR (1) KR20150095795A (en)
CN (1) CN104884075B (en)
CA (1) CA2893935C (en)
DK (1) DK2931299T3 (en)
ES (1) ES2718499T3 (en)
GB (2) GB201222455D0 (en)
SG (2) SG10201704712QA (en)
WO (1) WO2014091239A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
CA3095307A1 (en) * 2018-03-27 2019-10-03 Dentsply Sirona Inc. Methods of treatment of the dental pulp and filling root canals using anti inflammatory rinse solution and filling composition
WO2020037530A1 (en) * 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
US11845809B2 (en) * 2018-12-14 2023-12-19 Waterstone Pharmaceuticals(Wuhan) Co., Ltd. Maleate of SCY-635 and uses thereof in medicine
BR112022018929A2 (en) * 2020-03-26 2022-12-06 Farsight Medical Tech Shanghai Co Ltd CYCLOPHILIN INHIBITORS AND THEIR USES
JP7144703B2 (en) 2020-09-30 2022-09-30 ダイキン工業株式会社 Three-dimensional modeling composition and three-dimensional modeled object
KR102640323B1 (en) * 2021-11-30 2024-02-27 대우제약 주식회사 Stable nanosuspension of cyclosporine

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0597697A (en) * 1991-10-02 1993-04-20 Lion Corp Alveolar bone-regenerating agent
EP0708646A1 (en) * 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
HU215966B (en) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Oral multiple emulsion-preconcentrate containing cyclosporin
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
SE9601421D0 (en) * 1996-04-12 1996-04-12 Astra Ab New composition
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
DE19932157A1 (en) * 1999-07-13 2001-01-18 Pharmasol Gmbh Process for the gentle production of ultra-fine microparticles and nanoparticles
AR036853A1 (en) * 2001-10-19 2004-10-06 Isotechnika Inc CYCLOSPORINE ANALOG BLENDS AND ITS USE AS IMMUNOMODULATING AGENTS.
MEP89008A (en) * 2001-10-19 2011-12-20 Novel cyclosporin analog microemulsion preconcentrates
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
WO2005072701A1 (en) * 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
CN101048137A (en) * 2004-10-29 2007-10-03 诺瓦提斯公司 Spontaneously dispersible pharmaceutical compositions
CA2598204C (en) * 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
MX2007012762A (en) * 2005-04-12 2008-01-14 Elan Pharma Int Ltd Nanoparticulate and controlled release compositions comprising cyclosporine.
JP5449775B2 (en) * 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー Reduction of side effects with aromatase inhibitors used to treat breast cancer
KR20080065704A (en) * 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 Methods, compositions, and kits for the treatment of medical conditions
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
CN101032620B (en) * 2007-03-08 2010-05-19 上海凯昭医药科技有限公司 Cyclosporine emulsion and the preparing method
DE102008062373A1 (en) * 2007-12-21 2009-06-25 Essiger, Holger, Dr. Agent comprising at least one active ingredient having gum-growth activity
UA102414C2 (en) * 2008-11-06 2013-07-10 Дебио Решерш Фармасьютик С.А. Cycloundecadepsipeptide compounds for treating hepatitis c infections
KR100924236B1 (en) * 2009-06-23 2009-10-29 충남대학교산학협력단 Methods and apparatus for preparing ultra-fine particles with narrow particle size distribution
CN102085295B (en) * 2009-12-08 2012-09-05 华中科技大学 Nano-emulsion pharmaceutical composition containing spring onion extract for oral mucosa administration and preparation method thereof
IT1404931B1 (en) * 2010-06-11 2013-12-09 Medivis S R L OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
WO2012051194A1 (en) * 2010-10-12 2012-04-19 Allergan, Inc. Cyclosporin analogs
AU2012262513B2 (en) * 2011-05-27 2016-03-17 Allergan, Inc. A crystalline form of cyclosporine A, methods of preparation, and methods for use thereof

Also Published As

Publication number Publication date
GB2523707A (en) 2015-09-02
CA2893935C (en) 2021-11-02
US10471058B2 (en) 2019-11-12
US20200085825A1 (en) 2020-03-19
JP2016504314A (en) 2016-02-12
WO2014091239A1 (en) 2014-06-19
CN104884075A (en) 2015-09-02
GB201222455D0 (en) 2013-01-30
JP2019048860A (en) 2019-03-28
GB201511770D0 (en) 2015-08-19
CN104884075B (en) 2018-04-03
EP2931299B1 (en) 2019-02-06
JP6441809B2 (en) 2018-12-19
US20150313959A1 (en) 2015-11-05
JP6608028B2 (en) 2019-11-20
SG10201704712QA (en) 2017-07-28
EP3498290A1 (en) 2019-06-19
CA2893935A1 (en) 2014-06-19
KR20150095795A (en) 2015-08-21
DK2931299T3 (en) 2019-04-23
ES2718499T3 (en) 2019-07-02
EP2931299A1 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
HRP20181364T8 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
IL231536A (en) Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases
HK1209100A1 (en) N-substituted benzamides and their use in the treatment of pain n-
PL2928484T3 (en) Compounds useful in the treatment and/or care of the skin, hair and/or mucous membranes and their cosmetic or pharmaceutical compositions
IL236221A (en) Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases
IL237369A0 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
SG11201504447XA (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
IL232256A0 (en) Novel purine derivatives and their use in the treatment of disease
HK1199401A1 (en) Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
HK1199712A1 (en) 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis 18--67--3--17--4--2117-
IL271352B (en) Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
HK1203947A1 (en) Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions (halofuginol)
GB2515439B (en) Vesicular formulations for use in the treatment of reduced mobility
IL233875A (en) Composition and use thereof in the treatment of anal rhagades
ZA201402452B (en) Novel pyrimethanil formulations and uses thereof in the treatment of crops
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
IL234093A0 (en) Oral unit dosage forms and uses of same for the treatment of gaucher disease
HK1214771A1 (en) Formulations for use in the treatment of skin conditions
HK1206598A1 (en) Eprotirome for use in the prevention and or treatment of hair disorders and compositions thereof
GB201410869D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
SI2537528T1 (en) Pharmaceutical compositions containing beta- and alpha-galactosidase and their use in the treatment of gastroesophageal reflux disease